EVL.F · Evolus, Inc

-

Please sign in to comment on EVL.F

1 Comment

Admin

4 years ago

Evolus, Inc is currently in a long term uptrend where the price is trading 61.0% above its 200 day moving average.

From a valuation standpoint, the stock is 99.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 8.0.

Evolus, Inc's total revenue rose by 5.8% to $21M since the same quarter in the previous year.

Its net income has dropped by 663.0% to $-111M since the same quarter in the previous year.

Finally, its free cash flow grew by 86.6% to $-2M since the same quarter in the previous year.

Based on the above factors, Evolus, Inc gets an overall score of 4/5.

ISIN	US30052C1071
Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic
Exchange	F
CurrencyCode	EUR

Market Cap	648M
PE Ratio	None
Beta	0.97
Target Price	17.14
Dividend Yield	None

ABOUT

Evolus, Inc

Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

EVL.F · Evolus, Inc

-

Evolus, Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Evolus, Inc using a moving average strategy